Anders Kronborg, M.Sc. Economics
CHIEF EXECUTIVE OFFICER
Mr Kronborg is a seasoned executive with more than 25 years experience as CEO, CFO or COO. After he graduated as economist from Copenhagen University he spent 7 years in different roles in the ministry of Finance. From 2007-2015 Mr Kronborg worked for Kinnevik – a Swedish investment company listed in Stockholm – from 2012-2015 as COO for the whole group, getting private companies ready to go public and listing them together with other investors.
More recently (2015-2022) Mr Kronborg was CFO and interim CEO in LEO Pharma – a global Pharma company specialized in skin diseases.
Teis Vester, MSc
CHIEF FINANCIAL OFFICER
Teis Vester is an experienced finance executive with a background in group finance and auditing within Danish biotech.
Mr Vester has significant experience with financial planning, corporate accounting, financial reporting, controlling, and managing risk and compliance in both private and listed companies.
Mr Vester is Partner at Atlab, a specialized financial consultancy and previously has held roles as Head of Group Accounting at Symphogen and Group Financial Controller at Vestas and ISS. He started out his career in auditing at Deloitte and Lokalrevisorerne after earning a MSc in Business Economics and Auditing from Copenhagen Business School.
Thomas Jørgensen, MSc
VP CMC & CLINICAL OPERATIONS
Thomas Jørgensen has more than 30 years of experience working within the global pharmaceutical industry with clinical and pre-clinical program management, alliance management and CMC development for a variety of therapeutic modalities such as peptides, biologics, live biotherapeutics, and fermentation products.
Thomas’ former appointments include Senior Director, Savara, Director, Chr Hansen Microbiome Center, Program manager, Ferring Pharmaceutical, Alliance and Program manager, Symphogen, Group leader, CMC, Astra Zeneca and Research Scientist, Novo Nordisk.
Samra Sanni, PhD
VP DRUG RESEARCH
Samra Sanni is a biotech executive with a successful track record of discovery and development of novel peptide therapeutics within the cardio-metabolic space. Dr Sanni has significant experience from both smaller biotech and large pharma and has an impressive track record of bringing new molecules forward into clinical development. Previously, Dr Sanni served as Director of Pharmacology at Bainan Biotech and was previously employed at Antag Therapeutics and Novo Nordisk where she contributed to discovering and advancing new drugs in the company’s pipelines. Samra holds a Ph.D. in molecular pharmacology from the University of Copenhagen.
Anders Kronborg, M.Sc. Economics
CHIEF EXECUTIVE OFFICER
Mr Kronborg is a seasoned executive with more than 25 years experience as CEO, CFO or COO. After he graduated as economist from Copenhagen University he spent 7 years in different roles in the ministry of Finance. From 2007-2015 Mr Kronborg worked for Kinnevik – a Swedish investment company listed in Stockholm – from 2012-2015 as COO for the whole group, getting private companies ready to go public and listing them together with other investors.
More recently (2015-2022) Mr Kronborg was CFO and interim CEO in LEO Pharma – a global Pharma company specialized in skin diseases.
Dr Veng has operational leadership experience from both small and large organizations and has always worked at the intersection of business and innovation.
Most recently, Dr. Veng served as CEO and co-founder of Clinical Microbiomics. During her career, she has held various senior research leadership roles, including Head of Pharmacology and DMPK at LEO Pharma, preclinical team leader at Merck & Co, and H. Lundbeck. Dr. Veng has overseen the drug discovery, nomination and clinical transition of a number of drug candidates for inflammatory and neurological disorders.
Markus Weissbach
CHIEF MEDICAL OFFICER
Dr Markus Weissbach has more than 30 years of experience in the pharmaceutical, biotech, and CRO industry.
Besides several “C” positions in various biotech companies his previous appointments include Chief Medical Officer Europe at Novartis Vaccines and Diagnostics; Executive Chairman, CEO and President of Averion International Corp; President of ICON Clinical Research Plc., Europe; Director Clinical Research and Development at Takeda Euro R&D and International Medical Director at Knoll AG.
Dr. Weissbach has profound experience in therapeutic areas such as cardiology, vaccines, oncology, CNS, infectious and autoimmune diseases and in dealing and negotiating with regulatory authorities in Europe and USA. He has been instrumental in the successful NDAs and market launch of several NCEs and biologics in different indications.
Teis Vester, MSc
CHIEF FINANCIAL OFFICER
Teis Vester is an experienced finance executive with a background in group finance and auditing within Danish biotech.
Mr Vester has significant experience with financial planning, corporate accounting, financial reporting, controlling, and managing risk and compliance in both private and listed companies.
Mr Vester is Partner at Atlab, a specialized financial consultancy and previously has held roles as Head of Group Accounting at Symphogen and Group Financial Controller at Vestas and ISS. He started out his career in auditing at Deloitte and Lokalrevisorerne after earning a MSc in Business Economics and Auditing from Copenhagen Business School.
Thomas Jørgensen
VICE PRESIDENT OF DRUG RESEARCH
Thomas Jørgensen has more than 30 years of experience working within the global pharmaceutical industry with…
clinical and pre-clinical program management, alliance management and CMC development for a variety of therapeutic modalities such as peptides, biologics, live biotherapeutics, and fermentation products.
Thomas’ former appointments include Senior Director, Savara, Director, Chr Hansen Microbiome Center, Program manager, Ferring Pharmaceutical, Alliance and Program manager, Symphogen, Group leader, CMC, Astra Zeneca and Research Scientist, Novo Nordisk.
Samra Sanni, PhD
VICE PRESIDENT OF DRUG RESEARCH
Samra Sanni is a biotech executive with a successful track record of discovery and development of novel peptide therapeutics within the cardio-metabolic space.
Dr Sanni has significant experience from both smaller biotech and large pharma and has an impressive track record of bringing new molecules forward into clinical development. Previously, Dr Sanni served as Director of Pharmacology at Bainan Biotech and was previously employed at Antag Therapeutics and Novo Nordisk where she contributed to discovering and advancing new drugs in the company’s pipelines. Samra holds a Ph.D. in molecular pharmacology from the University of Copenhagen.
